Urothelial Bladder Carcinoma | Newly Approved Agents for Patients with Metastatic Urothelial Bladder Carcinoma Who Experience Disease Progression on Immune Checkpoint Inhibitor Therapy

Research To Practice | Oncology Videos

Featuring a roundtable discussion with Dr Elizabeth R Plimack, Dr Jonathan E Rosenberg, Mr Andrew Ruplin and Ms Cristina Salabao on the following topics:

• First-Line Systemic Therapy for Patients with Metastatic UBC (mUBC)
• • Overview of interdisciplinary care in UBC (0:00)
  • Counseling patients with newly diagnosed mUBC about prognosis and treatment options (3:50)
  • Recent advances in the management of mUBC (12:01)
  • Mechanism of action, efficacy and side effects of immune checkpoint inhibitors (18:50)
  • Design, results and clinical implications of the Phase III JAVELIN Bladder 100 trial evaluating first-line maintenance therapy with avelumab and best supportive care (BSC) versus BSC alone for patients with mUBC who had not experienced disease progression after induction chemotherapy (25:51)
  • Selection of first-line therapy for patients with mUBC (29:03)
  • Choice of up-front therapy for older patients with mUBC; role of PD-L1 expression in selection of therapy (36:57)
• Enfortumab Vedotin for Patients with Advanced UBC
• • Mechanism of action, activity and tolerability of enfortumab vedotin for advanced UBC (45:27)
  • Dose and schedule of administration of enfortumab vedotin; associated peripheral neuropathy, hyperglycemia and ocular toxicities (50:49)
  • Case: A woman in her early 70s with mUBC and a history of multiple sclerosis receives enfortumab vedotin after disease progression on neratinib/paclitaxel — Cristina Salabao, MSN, FNP-C (1:02:30)
  • Case: A woman in her late 60s with mUBC receives enfortumab vedotin after disease progression on sacituzumab govitecan — Andrew Ruplin, PharmD (1:10:12)
  • Case: A man in his early 80s receives enfortumab vedotin for mUBC — Elizabeth R Plimack, MD, MS (1:14:53)
  • Case: A man in his late 80s attains a stable response with enfortumab vedotin for mUBC — Jonathan E Rosenberg, MD (1:20:56)
• Role of Erdafitinib in the Treatment of Advanced UBC
• • Biologic rationale for, efficacy of and pharmaceutical considerations with erdafitinib for patients with mUBC and FGFR gene alterations (1:24:14)
  • Monitoring and management of ocular, skin and nail toxicities and hyperphosphatemia associated with erdafitinib (1:30:13)
  • Case: A woman in her early 70s develops rash, mucositis and nail changes after treatment with erdafitinib for mUBC with an FGFR3 alteration — Dr Rosenberg (1:37:50)
  • Case: A woman in her mid-70s with mUBC and an FGFR3 alteration receives erdafitinib after disease progression on cabozantinib/atezolizumab — Ms Salabao (1:39:15)
  • Case: A man in his early 60s develops hyperphosphatemia and central serous retinopathy after therapy with erdafitinib for mUBC with an FGFR alteration — Dr Ruplin (1:42:02)
  • Case: A man in his late 70s with mUBC with an FGFR3 alteration attains a good response to erdafitinib — Dr Plimack (1:47:32)
• Novel Agents and Approaches for Patients with mUBC
• • Biologic rationale for the combination of enfortumab vedotin and pembrolizumab; efficacy in the first-line setting for patients with advanced UBC (1:53:35)
  • Emerging data with the antibody-drug conjugates sacituzumab govitecan and trastuzumab deruxtecan for mUBC (1:59:02)
• Management of mUBC in the COVID-19 Era
• • Approach to therapy for patients with mUBC during the COVID-19 pandemic; role of telemedicine in patient care (2:06:08)
  • Impact of COVID-19 on clinical research and the care of patients with UBC (2:13:50)

NCPD and ACPE information and select publications